成癮性疾病藥物市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，細分類型（按最終用途、地區和競爭）

2022 年全球成癮藥物市場價值為 101.9 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為8.95%。全球成癮藥物市場是指專注於開發、生產和分銷用於治療成癮性疾病的藥物和療法。成癮障礙涵蓋多種病症，包括物質使用疾患（例如酒精、鴉片類藥物、興奮劑）、行為成癮（例如賭博、遊戲）以及各種同時發生的心理健康問題。

主要市場促進因素

成癮症盛行率上升

市場概況
預測期	2024-2028
2022 年市場規模	101.9億美元
2028 年市場規模	170.1億美元
2023-2028 年CAGR	8.95%
成長最快的細分市場	亞太地區
最大的市場	北美洲

全球成癮藥物市場正在經歷大幅成長，而這種擴張背後的主要驅動力之一是全球成癮症盛行率不斷上升。成癮障礙，包括物質使用障礙和行為成癮，已成為緊迫的全球健康問題。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球成癮障礙藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（菸草/尼古丁和電子煙、酒精、大麻、合成大麻素、處方藥和非處方藥、其他）
  • 依最終用途（醫院、診所、復健中心、其他）
  • 按地區
  • 按公司分類 (2022)
• 產品市場地圖
  • 按類型
  • 按最終用途
  • 按地區

第 6 章：北美成癮障礙藥物市場前景

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（菸草/尼古丁和電子煙、酒精、大麻、合成大麻素、處方藥和非處方藥、其他）
  • 依最終用途（醫院、診所、復健中心、其他）
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲成癮障礙藥物市場前景

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（菸草/尼古丁和電子煙、酒精、大麻、合成大麻素、處方藥和非處方藥、其他）
  • 依最終用途（醫院、診所、復健中心、其他）
  • 按國家/地區
• 歐洲：國家分析
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙

第 8 章：亞太地區成癮疾病藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（菸草/尼古丁和電子煙、酒精、大麻、合成大麻素、處方藥和非處方藥、其他）
  • 依最終用途（醫院、診所、復健中心、其他）
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國

第 9 章：南美洲成癮性疾病藥物市場前景

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（菸草/尼古丁和電子煙、酒精、大麻、合成大麻素、處方藥和非處方藥、其他）
  • 依最終用途（醫院、診所、復健中心、其他）
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲成癮性疾病藥物市場前景

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（菸草/尼古丁和電子煙、酒精、大麻、合成大麻素、處方藥和非處方藥、其他）
  • 依最終用途（醫院、診所、復健中心、其他）
  • 按國家/地區
• MEA：國家分析
  • 南非成癮障礙藥物
  • 沙烏地阿拉伯成癮障礙藥物
  • 阿拉伯聯合大公國成癮障礙藥物
  • 科威特成癮性疾病藥物

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第14章：競爭格局

• 商業概覽
• 產品供應
• 最近的發展
• 財務（據報導）
• 主要人員
• SWOT分析
  • Teva Pharmaceutical Industries Ltd
  • Abbott Laboratories Inc
  • GSK PLC
  • Cipla Ltd
  • Eli Lilly and Co Ltd
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Limited
  • Viatris Inc.
  • AstraZeneca PLC

第 15 章：策略建議

第 16 章：關於我們與免責聲明

Global Addiction Disorders Drugs Market has valued at USD 10.19 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.95% through 2028. The Global Addiction Disorders Drugs Market refers to the pharmaceutical industry segment focused on the development, production, and distribution of medications and therapies for the treatment of addiction disorders. Addiction disorders encompass a wide range of conditions, including substance use disorders (e.g., alcohol, opioids, stimulants), behavioral addictions (e.g., gambling, gaming), and various co-occurring mental health issues.

Key Market Drivers

Rising Prevalence of Addiction Disorders

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 10.19 Billion
Market Size 2028	USD 17.01 Billion
CAGR 2023-2028	8.95%
Fastest Growing Segment	Asia Pacific
Largest Market	North America

The Global Addiction Disorders Drugs Market is experiencing a significant surge in growth, and one of the primary drivers behind this expansion is the escalating prevalence of addiction disorders worldwide. Addiction disorders, encompassing substance use disorders and behavioral addictions, have become a pressing global health concern.

Addiction disorders are no longer confined to isolated pockets of society; they have become a pervasive global issue. The alarming prevalence of addiction is evident in the numbers: millions of individuals worldwide are struggling with various forms of addiction. This epidemic nature of addiction has spurred the growth of the market as it necessitates the development and distribution of effective treatments.

As addiction continues to touch the lives of countless individuals and communities, there has been a paradigm shift in how society views these disorders. Increasing awareness and recognition of addiction as a chronic, relapsing medical condition rather than a moral failing has led to a greater willingness to seek treatment. This change in perspective is instrumental in driving the market's growth.

Governments and healthcare organizations are actively investing in addressing addiction disorders as public health concerns. Funding for addiction treatment programs, the establishment of harm reduction strategies, and the implementation of regulatory frameworks have expanded access to care. This support has been a vital factor in boosting the growth of the addiction disorders drugs market.

The pharmaceutical industry has responded to the growing demand for addiction treatment with innovative drugs and therapies. Medications designed to reduce cravings, manage withdrawal symptoms, and support long-term recovery have been developed. The continuous stream of pharmaceutical innovation has diversified the market and improved treatment outcomes.

Rising prevalence has led to a recognition of the need for personalized treatment approaches. Not all individuals with addiction disorders are the same, and tailoring treatment plans to address individual needs and circumstances is crucial for success. This trend toward personalized medicine has driven market growth by increasing the effectiveness of addiction treatments.

The prevalence of addiction disorders has been further compounded by factors like stress and isolation, exacerbated by the COVID-19 pandemic. Consequently, the adoption of telemedicine and digital health solutions has grown substantially. These technologies have enabled individuals to access treatment and support remotely, thus expanding the reach of the market.

Opioid Epidemic

The Global Addiction Disorders Drugs Market is undergoing a transformation, with one of its most potent drivers of growth being the relentless opioid epidemic that has plagued many parts of the world. The opioid epidemic, characterized by a surge in opioid-related addiction and overdose deaths, has thrust addiction treatment and recovery into the spotlight.

The opioid epidemic is a global health crisis characterized by the widespread misuse and addiction to opioids, including prescription painkillers and illicit drugs like heroin. With millions affected by opioid use disorder, this crisis has become a prominent and urgent healthcare issue in many countries.

As the opioid epidemic continues to wreak havoc on communities and families, there is a growing demand for effective treatment options. The devastation wrought by opioids has prompted more individuals to seek help for their addiction, creating a surge in demand for addiction treatment services, including medications.

One of the key drivers of growth in the addiction disorders drugs market is the development and increased use of medications specifically designed to treat opioid use disorder (OUD). Medications such as buprenorphine, methadone, and naltrexone are used for opioid replacement therapy, helping individuals manage cravings, reduce withdrawal symptoms, and work toward long-term recovery.

In response to the opioid epidemic, harm reduction strategies have gained prominence. These strategies include the distribution of naloxone, an opioid overdose reversal medication, and the establishment of supervised injection facilities. These efforts underscore the importance of both prevention and treatment, boosting the market for addiction disorder drugs.

The pharmaceutical industry has responded to the opioid epidemic by investing in research and development of new medications and treatment approaches. These innovations aim to improve the effectiveness and accessibility of addiction treatment, particularly for those struggling with opioid addiction.

The opioid epidemic has played a significant role in changing public perceptions of addiction. Increasingly, addiction is viewed as a medical condition rather than a moral failing. This shift has reduced stigma and encouraged more individuals to seek treatment, further fueling the growth of the market.

Pharmaceutical Innovation

In the realm of healthcare, few areas have witnessed as profound a transformation as addiction treatment. The Global Addiction Disorders Drugs Market has evolved significantly, thanks to groundbreaking advancements in pharmaceutical innovation.

Pharmaceutical innovation has led to the development of a diverse range of medications specifically tailored to address addiction disorders. These innovative drugs target the underlying neurobiological mechanisms of addiction, offering a wider array of treatment options beyond traditional interventions.

Addiction disorders often involve intense cravings and distressing withdrawal symptoms when the substance of abuse is removed. Pharmaceutical innovations have yielded medications that effectively reduce cravings and manage withdrawal symptoms, making the recovery journey more manageable for individuals seeking treatment.

Different substances of abuse and behavioral addictions have unique characteristics and challenges. Pharmaceutical innovation has produced medications designed to address the specific needs of individuals with addiction to opioids, alcohol, stimulants, or other substances. This specialization allows for more effective treatment approaches.

One notable development in addiction treatment is the creation of long-acting formulations of medications. These formulations provide sustained therapeutic effects, reducing the need for frequent dosing and enhancing treatment adherence, thereby improving overall outcomes.

Relapse is a common challenge in addiction recovery. Pharmaceutical innovations have led to medications that not only aid in initial detoxification but also reduce the risk of relapse by blocking the reinforcing effects of substances or reducing the perceived reward of addictive behaviors.

Many individuals with addiction disorders also suffer from co-occurring mental health conditions. Pharmaceutical innovations have resulted in drugs that can effectively address both addiction and underlying psychiatric disorders, providing a holistic approach to treatment.

Polydrug use, where individuals abuse multiple substances simultaneously, poses unique challenges in treatment. Pharmaceutical innovation is creating medications and treatment regimens that can address the complex issues associated with polydrug use.

Reducing Stigma

Stigma has long been a formidable barrier to individuals seeking help for addiction disorders. However, recent efforts to reduce the stigma associated with addiction are not only changing the way society views these conditions but also playing a crucial role in boosting the growth of the Global Addiction Disorders Drugs Market.

Stigma associated with addiction has deep historical roots, often leading to discrimination, isolation, and shame for those affected. This stigma has been a significant deterrent for individuals seeking help, perpetuating a cycle of suffering and limited access to care.

In recent years, there has been a growing recognition that addiction is a medical condition rather than a moral failing. This shift in public perception is the foundation for reducing stigma. As society becomes more empathetic and understanding, individuals are more likely to seek treatment.

Reducing stigma around addiction creates a supportive environment where individuals feel less ashamed to acknowledge their struggles and seek help. This shift in behavior is driving an increase in the number of people entering addiction treatment programs, thus expanding the market for addiction disorder drugs.

As stigma decreases, individuals are more likely to access evidence-based addiction treatments, including medications. These treatments have been proven effective in reducing cravings, managing withdrawal symptoms, and supporting long-term recovery.

Governments and healthcare organizations are increasingly recognizing the importance of addressing addiction as a public health issue. With a focus on reducing stigma, they are implementing public awareness campaigns and educational programs that highlight the need for compassionate and evidence-based treatment.

Community-based initiatives, such as peer support groups and harm reduction programs, play a pivotal role in reducing stigma. By fostering a sense of belonging and understanding, these programs encourage individuals to seek help and engage in treatment.

Accurate and empathetic media representation of addiction and recovery stories helps dispel stereotypes and reduces stigma. Media campaigns that feature real-life recovery journeys have a positive impact on public perception and contribute to market growth.

Corporations and healthcare institutions are increasingly involved in efforts to reduce stigma. Employee assistance programs, mental health benefits, and workplace initiatives that promote awareness and understanding of addiction are creating a supportive environment for employees seeking help.

Key Market Challenges

Access to Treatment

Accessibility to addiction treatment services remains a challenge, particularly in rural or underserved areas. Geographic disparities in access to addiction medications and counseling can leave many individuals without the support they need to recover.

Affordability

The cost of addiction treatment medications and therapies can be prohibitively high for many individuals. Insurance coverage for addiction treatment varies, and not everyone has access to affordable options. This financial barrier can prevent people from receiving necessary care.

Emerging Substances and Behaviors

The market must adapt to address emerging substances of abuse and behavioral addictions, such as designer drugs and compulsive gaming. Staying ahead of these trends requires ongoing research and innovation.

Key Market Trends

Pharmacogenomics and Biomarkers

Research in pharmacogenomics and biomarkers is paving the way for more precise drug selection and dosing in addiction treatment. Genetic markers can help identify individuals who may respond better to certain medications, leading to more targeted interventions.

Expanded Range of Medications

Ongoing research and development efforts are expanding the range of medications available for addiction disorders. In addition to existing treatments for opioids and alcohol use disorder, there is a growing focus on developing drugs for stimulant use disorders and emerging substances of abuse.

Integration of Behavioral and Medication-Based Therapies

An integrated approach that combines medication-based treatments with behavioral therapies is becoming increasingly prevalent. This holistic approach addresses the psychological and physiological aspects of addiction simultaneously, enhancing the chances of long-term recovery.

Segmental Insights

Form Type Insights

Based on the category of Type, the tobacco/nicotine and vaping sector claimed the largest portion of total revenue in 2022. This sector's prominence can be attributed to the rising prevalence of tobacco addiction within the population. It is estimated that approximately 22.3% of the global population is tobacco users, resulting in the annual loss of 8 million lives. Tobacco is often considered a gateway substance, as it can lead to the use and abuse of other substances. Teenagers who smoke are 22 times more likely to use cocaine, 8 times more likely to use marijuana, and 3 times more likely to consume alcohol compared to non-smokers. Tobacco is associated with causing harm to nearly every organ in the body, including lung impairment and decreased lung function. This underscores the pressing need for addiction treatment for individuals dealing with such health conditions.

On the other hand, the alcohol sector is anticipated to exhibit the most rapid growth rate in the foreseeable future, owing to its widespread consumption, easy availability, and increased social acceptance, leading to higher global consumption. According to estimates from the World Health Organization (WHO), 3 million deaths occur worldwide each year due to the harmful use of alcohol, representing 5.3% of all fatalities. Following tobacco addiction, alcohol abuse is the second most prevalent form of substance abuse on a global scale. Alcohol use disorder arises when a person's drinking habits result in distress or harm, affecting approximately 10% of adult men and 5% of adult women. The market for alcohol addiction treatment is projected to experience significant growth during the forecast period, including the utilization of key drugs such as disulfiram, acamprosate, and naltrexone for alcohol addiction treatment.

End-Use Insights

Based on End-Use, the hospital segment within the industry emerged as the dominant force in 2022, securing the largest portion of the total revenue. This dominance can be attributed to several factors. Firstly, there is a delay in the detection of addiction-related conditions due to social stigmatization among patients. This leads to reluctance on their part to seek treatment, resulting in the development of severe addiction cases that necessitate hospitalization for comprehensive addiction treatment. This, in turn, propels the growth of this segment. Additionally, individuals engaged in prolonged substance abuse often suffer from other health issues, such as cardiovascular disease, stroke, cancer, HIV/AIDS, Hepatitis B and C, lung ailments, and mental disorders. Hospitals, as primary treatment centers, also offer services to address these health conditions linked to substance abuse.

Conversely, the rehabilitation centers segment is expected to exhibit the most rapid CAGR during the forecast period. Rehabilitation centers provide a wider array of treatment options, amenities, and specialized care, including dual diagnosis, making them the preferred choice for patients requiring long-term addiction treatment programs, which may span from six months to a year or longer. Furthermore, rehabilitation centers are forging partnerships with hospitals to enhance patient care. However, it's worth noting that the high cost associated with addiction treatment within rehabilitation centers is anticipated to act as a hindrance to the growth of this segment. For instance, a general outpatient rehab program costs between USD 1,400 to USD 10,000 over 30 days, averaging around USD 5,700 per month. It's important to note that addiction treatment pharmaceutical products represent only a fraction of these overall costs.

Regional Insights

North America asserted its dominance within the industry in 2022 and held the largest share of the overall revenue. This segment is poised for further growth, maintaining its commanding position throughout the forecast period. Several factors contribute to this sustained growth, including an expanding population exposed to addiction, well-structured reimbursement policies, the legalization of marijuana in various states, and the presence of well-developed healthcare sectors in the region. According to data from the CDC, nearly 17% of the U.S. population engages in binge alcohol consumption, while approximately 6% are involved in heavy drinking. Furthermore, nicotine addiction is particularly prevalent in the United States, with nearly 40 million adults addicted to tobacco smoking. This creates a significant opportunity for the addiction treatment market in North America.

Additionally, both public and private organizations in the region are consistently focused on raising awareness about the serious risks associated with substance abuse and drug addiction. This proactive approach serves as a catalyst for the growth of the regional market. On the other hand, the Asia Pacific region is projected to register the highest CAGR during the forecast period. This growth can be attributed to the expansion of key industry players into Asian countries, coupled with the development of healthcare infrastructure and supportive government initiatives aimed at promoting the adoption of nicotine, alcohol, and drug addiction treatments. Furthermore, the increasing incidence of alcohol, tobacco, and opioid addiction in Asian countries will contribute to the expansion of the regional market. Nevertheless, the lack of public awareness and healthcare disparities in emerging economies may pose challenges to growth in this region.

Key Market Players

Teva Pharmaceutical Industries Ltd

Abbott Laboratories Inc

GSK PLC

Cipla Ltd

Eli Lilly and Co Ltd

Novartis AG

Sun Pharmaceutical Industries Ltd

Dr. Reddy's Laboratories Limited

Viatris Inc.

AstraZeneca PLC

Report Scope:

In this report, the Global Addiction Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Addiction Disorders Drugs Market, By Type:

• Tobacco/Nicotine & Vaping
• Alcohol
• Marijuana
• Synthetic Cannabinoids
• Prescription & Over-the-Counter Medications
• Others

Addiction Disorders Drugs Market, By End-Use:

• Hospitals
• Clinics
• Rehabilitation Centers
• Others

Addiction Disorders Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Addiction Disorders Drugs Market.

Available Customizations:

• Global Addiction Disorders Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Addiction Disorders Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Tobacco/Nicotine & Vaping, Alcohol, Marijuana, Synthetic Cannabinoids, Prescription & Over-the-Counter Medications, Others)
  • 5.2.2. By End-Use (Hospitals, Clinics, Rehabilitation Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By End-Use
  • 5.3.3. By Region

6. North America Addiction Disorders Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Tobacco/Nicotine & Vaping, Alcohol, Marijuana, Synthetic Cannabinoids, Prescription & Over-the-Counter Medications, Others)
  • 6.2.2. By End-Use (Hospitals, Clinics, Rehabilitation Centers, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Addiction Disorders Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Canada Addiction Disorders Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Mexico Addiction Disorders Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By End-Use

7. Europe Addiction Disorders Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Tobacco/Nicotine & Vaping, Alcohol, Marijuana, Synthetic Cannabinoids, Prescription & Over-the-Counter Medications, Others)
  • 7.2.2. By End-Use (Hospitals, Clinics, Rehabilitation Centers, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Addiction Disorders Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By End-Use
  • 7.3.2. United Kingdom Addiction Disorders Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By End-Use
  • 7.3.3. France Addiction Disorders Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By End-Use
  • 7.3.4. Italy Addiction Disorders Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Addiction Disorders Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By End-Use

8. Asia-Pacific Addiction Disorders Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Tobacco/Nicotine & Vaping, Alcohol, Marijuana, Synthetic Cannabinoids, Prescription & Over-the-Counter Medications, Others)
  • 8.2.2. By End-Use (Hospitals, Clinics, Rehabilitation Centers, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Addiction Disorders Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By End-Use
  • 8.3.2. Japan Addiction Disorders Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By End-Use
  • 8.3.3. India Addiction Disorders Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By End-Use
  • 8.3.4. Australia Addiction Disorders Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By End-Use
  • 8.3.5. South Korea Addiction Disorders Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By End-Use

9. South America Addiction Disorders Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Tobacco/Nicotine & Vaping, Alcohol, Marijuana, Synthetic Cannabinoids, Prescription & Over-the-Counter Medications, Others)
  • 9.2.2. By End-Use (Hospitals, Clinics, Rehabilitation Centers, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Addiction Disorders Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By End-Use
  • 9.3.2. Argentina Addiction Disorders Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By End-Use
  • 9.3.3. Colombia Addiction Disorders Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By End-Use

10. Middle East and Africa Addiction Disorders Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Tobacco/Nicotine & Vaping, Alcohol, Marijuana, Synthetic Cannabinoids, Prescription & Over-the-Counter Medications, Others)
  • 10.2.2. By End-Use (Hospitals, Clinics, Rehabilitation Centers, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Addiction Disorders Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Saudi Arabia Addiction Disorders Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By End-Use
  • 10.3.3. UAE Addiction Disorders Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By End-Use
  • 10.3.4. Kuwait Addiction Disorders Drugs Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Teva Pharmaceutical Industries Ltd
  • 14.6.2. Abbott Laboratories Inc
  • 14.6.3. GSK PLC
  • 14.6.4. Cipla Ltd
  • 14.6.5. Eli Lilly and Co Ltd
  • 14.6.6. Novartis AG
  • 14.6.7. Sun Pharmaceutical Industries Ltd
  • 14.6.8. Dr. Reddy's Laboratories Limited
  • 14.6.9. Viatris Inc.
  • 14.6.10. AstraZeneca PLC

15. Strategic Recommendations

16. About Us & Disclaimer